10-Q: Prothena Navigates R&D Shifts, Reports Q3 Loss Amid Restructuring

Prothena Corporation plc reported a significant net loss of $222.5 million for the nine months ended September 30, 2025, driven by R&D wind-downs and a corporate restructuring, while advancing key partnered neurodegenerative programs.

Summary

• Reported a net loss of $222.5 million for the nine months ended September 30, 2025, a significant increase from $64.3 million in the same period of 2024.
• Total revenue for the nine months ended September 30, 2025, decreased by 93% to $9.7 million, compared to $133.0 million in the prior year, primarily due to the absence of large upfront milestone payments received in 2024.
• Research and development (R&D) expenses decreased by 30% to $120.3 million for the nine months ended September 30, 2025, mainly due to the wind-down of the PRX012 program and lower personnel and manufacturing expenses.
• General and administrative (G&A) expenses decreased by 7% to $46.7 million for the nine months ended September 30, 2025.
• Incurred $33.1 million in restructuring costs for the nine months ended September 30, 2025, following the discontinuation of birtamimab development and an approximate 63% workforce reduction in June 2025.
• Cash and cash equivalents stood at $330.8 million as of September 30, 2025, down from $471.4 million at December 31, 2024.
• Accumulated deficit reached $1.3 billion as of September 30, 2025.
• Roche plans to initiate the Phase 3 PARAISO clinical trial for prasinezumab in early-stage Parkinson's disease by the end of 2025, based on positive trends from Phase 2b PADOVA data.
• Novo Nordisk initiated the Phase 3 CLEOPATTRA clinical trial for coramitug in ATTR-CM in September 2025.
• BMS-986446 for Alzheimer's disease received FDA Fast Track designation in October 2025, and Bristol Myers Squibb (BMS) initiated a Phase 2 clinical trial (TargetTau-1) in Q1 2024 and a Phase 1 subcutaneous trial in Q2 2025.
• A Phase 1 first-in-human clinical trial for PRX019 for neurodegenerative diseases was initiated in November 2024.
• A valuation allowance of $43.2 million was recorded against federal deferred tax assets, reflecting uncertainty about their future realization.

Sentiment

Score: 3

Explanation: While there are positive clinical advancements for partnered programs (prasinezumab, coramitug, BMS-986446, PRX019), the overall financial performance is significantly negative with a substantial increase in net loss, a sharp decline in revenue, and a large workforce reduction following a program failure. The need for future capital and the recording of a deferred tax asset valuation allowance also contribute to a cautious outlook.

Positives

• Roche is advancing prasinezumab into a Phase 3 PARAISO clinical trial for early-stage Parkinson's disease by the end of 2025, citing potential clinical benefit from Phase 2b PADOVA data.
• Novo Nordisk initiated the Phase 3 CLEOPATTRA clinical trial for coramitug in ATTR-CM in September 2025, indicating continued development of the asset.
• BMS-986446 for Alzheimer's disease received FDA Fast Track designation in October 2025, which may expedite its development and review process.
• BMS initiated the Phase 2 TargetTau-1 clinical trial for BMS-986446 in Q1 2024 and a Phase 1 subcutaneous trial in Q2 2025, demonstrating continued progress in this partnered program.
• The Phase 1 first-in-human clinical trial for PRX019 was initiated in November 2024, marking progress for this neurodegenerative disease candidate.
• R&D expenses decreased by 30% for the nine months ended September 30, 2025, primarily due to strategic program wind-downs and lower personnel and manufacturing costs, indicating cost management efforts.

Negatives

• Reported a significant net loss of $222.5 million for the nine months ended September 30, 2025, a substantial increase from $64.3 million in the prior year.
• Total revenue decreased by 93% to $9.7 million for the nine months ended September 30, 2025, primarily due to the absence of large upfront milestone payments received in the prior year.
• Discontinuation of birtamimab development in May 2025 due to the failure of its Phase 3 AFFIRM-AL clinical trial to meet primary or secondary endpoints.
• Implemented an approximate 63% reduction in workforce in June 2025, resulting in $33.1 million in restructuring costs for the nine months ended September 30, 2025.
• Cash and cash equivalents decreased by $140.5 million during the nine months ended September 30, 2025, indicating significant cash burn.
• Accumulated deficit reached $1.3 billion as of September 30, 2025, highlighting a history of operating losses.
• Recorded an expense to establish a valuation allowance of $43.2 million against federal deferred tax assets, signaling management's uncertainty about realizing future tax benefits.
• Interest income decreased by 44% for the nine months ended September 30, 2025, due to lower cash balances and lower yields.

Risks

• Anticipate incurring losses for the foreseeable future and may never sustain profitability.
• Will require additional capital to fund operations, and if unable to obtain such capital, will be unable to successfully develop and commercialize drug candidates.
• Success is largely dependent on research and development programs; drug candidates may not be successfully discovered, developed, obtained regulatory approval for, or commercialized.
• Collaborations with Roche, BMS, and Novo Nordisk may not realize anticipated benefits, including receiving anticipated milestone payments.
• Clinical trials of drug candidates may be prolonged, delayed, suspended, or terminated, leading to additional costs and delayed revenue.
• Even if any drug candidates receive regulatory approval, if such approved product does not achieve broad market acceptance, the revenues generated from sales will be limited.
• Inability to adequately protect or enforce intellectual property relating to drug candidates will harm the ability to successfully commercialize them.
• Future success depends on the ability to retain key personnel and to attract, retain, and motivate qualified personnel.
• Exposure to credit risk in the event of a default by financial institutions holding cash and cash equivalents, as deposits exceed federally insured limits.
• Exposure to foreign currency risk, particularly from agreements with contract manufacturers for drug supplies denominated in euros.
• Dependence on third-party manufacturers to supply nonclinical and clinical trial supplies, and potentially commercial supplies, with risks of non-performance, damage, or non-compliance.
• Potential for breaches or similar disruptions of information technology systems or data, including from cyberattacks, leading to business disruption or data loss.
• Changes in and failures to comply with U.S. and foreign privacy and data protection laws, regulations, and standards may adversely affect business.
• The regulatory approval processes of the FDA, EMA, and other comparable authorities are lengthy, time-consuming, and inherently unpredictable.
• The FDA or other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction.
• Both before and after marketing approval, drug candidates are subject to ongoing regulatory requirements and continued review, with potential for sanctions or suspension of sales for non-compliance.
• If side effects are identified during development or after market approval, lengthy additional clinical trials, development discontinuation, labeling changes, or market withdrawal may be required.
• Dealing with hazardous materials and compliance with environmental laws and regulations can be expensive and restrict business operations.
• The markets for drug candidates are subject to intense competition, which may render drug candidates noncompetitive or obsolete.
• Drug candidates for which approval is sought as biologic products may face competition from biosimilars sooner than anticipated.
• May be unable to maintain the benefits associated with Orphan Drug Designation, including potential for supplemental market exclusivity.
• A Fast Track designation by the FDA, even if granted, may not lead to faster development or regulatory review and does not increase the likelihood of marketing licensure.
• Subject to healthcare and other laws and regulations, including anti-bribery, anti-kickback, fraud and abuse, false claims, and physician payment transparency laws, which could expose the company to sanctions.
• If a successful product liability or clinical trial claim or series of claims is brought for uninsured liabilities or in excess of insured liabilities, substantial liability could be incurred.
• Dependence on third-party suppliers for key raw materials used in manufacturing processes, with risks of supply interruption or quality issues.
• May be subject to claims challenging the inventorship or ownership of patents and other intellectual property.
• May not be able to protect intellectual property rights throughout the world, as patent laws vary by country.
• Licenses for third-party patent rights may be subject to early termination if the company fails to comply with obligations.
• Litigation regarding patents, patent applications, and other proprietary rights may be expensive and time-consuming, causing delays and harming operations.
• If trademarks and trade names are not adequately protected, the company may not be able to build name recognition.
• May be unable to adequately prevent disclosure of trade secrets and other proprietary information.
• May be subject to claims that employees, collaborators, or advisors have wrongfully used or disclosed alleged trade secrets of third parties.
• Intellectual property rights do not necessarily address all potential threats to competitive advantage.
• The market price of ordinary shares may fluctuate widely due to various factors.
• Percentage ownership in Prothena may be diluted in the future due to equity issuances for acquisitions, capital raising, or equity awards.
• If unable to maintain effective internal controls, the business could be adversely affected.
• If treated as a passive foreign investment company (PFIC) for U.S. federal income tax purposes, it could result in adverse U.S. federal income tax consequences to United States holders of ordinary shares.
• May not be able to successfully maintain tax rates, which could adversely affect business.
• Irish law differs from U.S. law and may afford less protection to holders of ordinary shares.
• The operation of the Irish Takeover Rules may affect the ability of certain parties to acquire ordinary shares.
• Irish law requires shareholders to renew every five years the authority of the Board of Directors to issue shares and to do so for cash without applying the statutory pre-emption right, and failure to renew could limit capital raising.
• Do not anticipate paying cash dividends, requiring shareholders to rely on ordinary share appreciation for any return on investment.
• Dividends paid may be subject to Irish dividend withholding tax.
• Ordinary shares received by means of a gift or inheritance could be subject to Irish capital acquisitions tax.

Future Outlook

Management believes existing cash and cash equivalents are sufficient to meet obligations for at least the next twelve months. However, additional capital will be required to operate beyond this period, or for increased R&D spending, licenses, or acquisitions. Future capital needs are expected to be financed through payments from existing collaborations (Roche, BMS, Novo Nordisk), other collaborative agreements, or through public or private equity or debt financings. Roche plans to initiate the Phase 3 PARAISO clinical trial for prasinezumab by the end of 2025. Novo Nordisk initiated the Phase 3 CLEOPATTRA clinical trial for coramitug in September 2025, with Phase 2 results expected in November 2025. The company expects full year 2025 net cash used in operating and investing activities to be approximately $170 million to $178 million.

Management Comments

• "Based on our current business plans, we believe that our existing cash and cash equivalents at September 30, 2025, are sufficient to meet our obligations for at least the next twelve months."
• "To operate beyond such period, or if we elect to increase our spending on research and development programs significantly above current long-term plans or enter into potential licenses and/or other acquisitions of complementary technologies, products or companies, we may need additional capital."
• "Additionally, in order to develop and obtain regulatory approval for our potential products we will need to raise substantial additional capital."
• "We expect to continue to finance future capital needs that exceed our existing cash and cash equivalents from payments pursuant to our agreements with Roche, BMS, and Novo Nordisk, and, to the extent necessary, other collaborative agreements with corporate partners, or other arrangements, and through proceeds from public or private equity or debt financings, and loans including pursuant to the Amended Distribution Agreement."
• "We cannot assume that such additional financings will be available on acceptable terms, if at all, and such financings may only be available on terms dilutive to our shareholders."
• "Assuming no significant change in our business, we expect the full year 2025 net cash used in operating and investing activities to be approximately $170 million to $178 million."

Industry Context

Prothena operates in the high-risk, high-reward biotechnology sector, focusing on neurodegenerative and rare peripheral amyloid diseases, areas with significant unmet medical needs. The company's strategy of partnering with major pharmaceutical companies like Roche, BMS, and Novo Nordisk for late-stage development is a common industry approach to share costs and leverage broader resources. The discontinuation of birtamimab highlights the inherent high failure rate in clinical trials, even in late stages. The FDA Fast Track designation for BMS-986446 underscores regulatory recognition of the potential for novel therapies in Alzheimer's disease.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises, stock price volatility, and no anticipated cash dividends, relying solely on share appreciation. Irish legal frameworks also introduce specific considerations regarding share issuance and takeovers.
• Employees experienced a significant workforce reduction of approximately 63% in June 2025 as part of a corporate restructuring, impacting job security and morale.
• Patients and potential customers may benefit from the advancement of partnered programs (prasinezumab, coramitug, BMS-986446, PRX019) towards potential new treatments for Parkinson's, Alzheimer's, and ATTR amyloidosis. However, the discontinuation of birtamimab means no treatment for AL amyloidosis from this program.
• Creditors and suppliers may face risks related to the company's financial stability and ability to meet obligations, which are dependent on future capital raises and collaboration payments. Restructuring activities also include contract termination costs.

Next Steps

• Roche plans to initiate the Phase 3 PARAISO clinical trial for prasinezumab for early-stage Parkinson's disease by the end of 2025.
• Novo Nordisk initiated the Phase 3 CLEOPATTRA clinical trial for coramitug in ATTR-CM in September 2025.
• Results from Novo Nordisk's Phase 2 clinical trial of coramitug in ATTR amyloidosis with cardiomyopathy are planned to be presented at the American Heart Association Scientific Sessions in November 2025.
• BMS initiated a Phase 1 clinical trial to assess drug levels, tolerability, and absolute biological availability of single subcutaneous dose of BMS-986446 in healthy participants in Q2 2025.
• The Phase 2 PASADENA and Phase 2b PADOVA open-label extension studies for prasinezumab will continue to further explore observed effects.
• The company will continue to explore strategic interest for further development of its wholly-owned and unpartnered clinical and preclinical-stage programs.
• Substantially all cash payments related to the June 2025 restructuring plan are expected to be paid out by the end of the fourth quarter of 2025.
• The company is evaluating the impact of new FASB accounting standards (ASU 2024-03 and ASU 2023-09) on its financial statement disclosures.

Key Dates

Recommendation

The company is in a transitional phase, marked by a significant net loss, a sharp decline in revenue, and a substantial workforce reduction following a program failure. These factors indicate considerable financial headwinds and operational restructuring. However, the continued advancement of multiple partnered programs (prasinezumab, coramitug, BMS-986446, PRX019) into later-stage clinical trials, coupled with an FDA Fast Track designation for BMS-986446, provides a basis for future potential. While the current cash position is deemed sufficient for the next 12 months, the explicit need for additional capital thereafter introduces future financing risk. Given the high-risk nature of drug development, the current financial challenges, and the long timeline to potential commercialization, a 'Hold' recommendation is appropriate. Investors should closely monitor the progress of key clinical trials, the company's ability to secure future financing, and its ongoing efforts to manage costs and pipeline development.

Keywords

Biotechnology, Neurodegenerative, Parkinson's disease, Alzheimer's disease, ATTR amyloidosis, Prasinezumab, BMS-986446, PRX019, Coramitug, Clinical trials, Phase 3, Fast Track, SEC filing, 10-Q, Financial results, Restructuring, R&D, Collaboration, Roche, Bristol Myers Squibb, Novo Nordisk, Protein dysregulation, Alpha-synuclein, Tau, Amyloid